High-rolling investors have positioned themselves bullish on Altimmune ALT, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ALT often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for Altimmune. This is not a typical pattern.
The sentiment among these major traders is split, with 50% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $41,891, and 7 calls, totaling $550,860.
Expected Price Movements
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $7.0 to $12.0 for Altimmune over the recent three months.
Volume & Open Interest Development
In terms of liquidity and interest, the mean open interest for Altimmune options trades today is 910.14 with a total volume of 3,378.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Altimmune's big money trades within a strike price range of $7.0 to $12.0 over the last 30 days.
Altimmune Option Activity Analysis: Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT | CALL | TRADE | BULLISH | 06/20/25 | $3.3 | $3.0 | $3.2 | $12.00 | $319.6K | 409 | 1.0K |
| ALT | CALL | TRADE | BULLISH | 11/15/24 | $0.8 | $0.75 | $0.8 | $10.00 | $71.9K | 3.5K | 390 |
| ALT | PUT | SWEEP | BULLISH | 11/15/24 | $1.05 | $1.0 | $1.0 | $11.00 | $41.8K | 250 | 926 |
| ALT | CALL | SWEEP | BEARISH | 12/06/24 | $3.9 | $3.7 | $3.7 | $7.50 | $37.0K | 370 | 100 |
| ALT | CALL | SWEEP | NEUTRAL | 11/29/24 | $3.5 | $3.2 | $3.3 | $7.00 | $33.0K | 375 | 100 |
About Altimmune
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
In light of the recent options history for Altimmune, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Current Position of Altimmune
- Currently trading with a volume of 7,319,895, the ALT's price is up by 6.15%, now at $10.07.
- RSI readings suggest the stock is currently may be overbought.
- Anticipated earnings release is in 133 days.
What Analysts Are Saying About Altimmune
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $26.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * In a cautious move, an analyst from UBS downgraded its rating to Buy, setting a price target of $26.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Altimmune, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
